The virulence of different vaccine and wild-type yellow fever (YF) viruses for young adult mice was compared using both intracerebral and intranasal routes of administration. Thirty-five different YF viruses killed mice within 12 days following intracerebral inoculation. In contrast, only seven of those examined killed mice following intranasal administration; these were Asibi virus (YF-AS), the French neurotropic vaccine, two out of three 17DD vaccine substrain viruses (Brazil, Colombia but not Dakar) and three out of six wild-type isolates (YF-B7, YF-B12 and YF-B 15). None of eight distinct preparations from the 17D-204 vaccine substrain was virulent by the intranasal route. Thus, strains of YF virus can be distinguished on the basis of their virulence for mice if the intranasal route is used. Evidence of heterogeneity in mouse virulence within the populations was obtained using large and small plaques selected from wild-type stocks of virus. Following intranasal inoculation, a YF-AS small plaque variant was more virulent than either its parent virus or a large plaque variant. On the other hand, a large and a small plaque variant from a nonvirulent wild-type strain could not be distinguished in these tests.
INTRODUCTION
Yellow fever (YF) virus is the prototype of the family Flaviviridae (Westaway et al., 1985) and is both viscerotropic, causing liver disease, and neurotropic, causing encephalitis (Theiler, 1951) . Live attenuated vaccines have been developed from two distinct origins; French workers in Dakar, Senegal, developed a vaccine strain from a wild-type virus isolate by serial intracerebral mouse brain passage of the virus. This is the French neurotropic vaccine (YF-FNV; Mathis et al., 1928) . Unfortunately, post-vaccination encephalitis has been reported in children, and the World Health Organization (WHO) recommended that this vaccine should not be administered to children under the age of 14 years (WHO, 1959) .
Independently, a different vaccine virus was developed after isolation of wild-type virus from a mild case of YF in Ghana (YF-Asibi); the virus was serially passaged extensively in mouse tissue, and subsequently chick embryo tissue, until a variant designated YF-17D, with significantly reduced neurovirulence for rhesus monkeys, was isolated (Theiler & Smith, 1937) . This is used as the basis of present day vaccine viruses. Two substrains of 17D were developed, namely 17D-204 and 17DD, which have been made independently and are both used as vaccines today. Some vaccine lots have been subcultured in excess of 300 times and have been found to be either overattenuated or show increased neurovirulence (Fox et al., 1942; Theiler, 1951) . It has been recently proposed that research towards the development of in vitro and improved in vivo markers of neurotropism/neurovirulence and towards the selection of a vaccine free of these characteristics should be pursued (WHO, 1985a, b) .
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Studies by Theiler (1930 Theiler ( , 1951 had shown that YF viruses were neurotropic in mice and later studies by Fitzgeorge & Bradish (1980a, b) and Liprandi (1981) showed that it was possible to distinguish strains of YF virus but they could not explain differences in neurovirulence between YF viruses. In this paper, we compare the neurovirulence of both vaccine and wild-type strains of YF virus after intracerebral or intranasal inoculation. The results will show that significant differences in the neuroinvasiveness (i.e. the ability of a virus to invade the central nervous system) of the strains were detected after intranasal inoculation.
METHODS
Viruses. The 17D vaccine viruses used are shown in Table 1 . The wild-type strains have been described in detail previously (Gould et al., 1985) . Briefly, representatives of all types of YF viruses were included, i.e. Asibi virus (the parent of 17D vaccine viruses), 17D and 17DD vaccine viruses, French neurotropic vaccine virus, and wild-type viruses from Africa and South America. Vaccine viruses were received as freeze-dried material and reconstituted in water or saline except for YF-17DD-Braz-1 which had been passed once in BHK-21 cells prior to receipt. Each virus (vaccine or wild-type) was given one intracerebral passage in newborn mice (strain TO). When mice appeared sick, brains were removed and 20~o mouse brain suspensions were prepared in Liebovitz-LI5 medium (LI5) containing 2~ foetal calf serum (FCS). These were stored at -70 °C in 0.2 ml aliquots.
Mice. Random bred (strain TO) white mice 4 to 5 weeks old, weighing about 22 g, were obtained from T. S. Tuck and Son, Battlesbridge, Essex, U.K. and were used 2 to 7 days after delivery. BALB/c inbred mice came from the London School of Hygiene and Tropical Medicine breeding colony and weighed about 15 g at 5 weeks of age.
Inoculation of mice lntracerebral. Groups of six or more mice were inoculated intracerebrally with 20 p.1 vol. of virus diluted in phosphate-buffered saline (PBS).
Intranasal. Groups of eight or more mice were inoculated under light ether anaesthesia by placing a 20 ktl vol. of virus diluted in PBS on the nostrils.
Plaque assay and selection ofplaque variants. Infectivity titrations of virus preparations were performed in Vero cells using LI5 medium containing 5% FCS according to the procedure of Gould et al. (1985) . For selection of plaque variants, Vero cell monolayers were prepared in 6-cm Petri dishes using Eagle's MEM (EMEM) containing 5 % FCS. Serial tenfold dilutions of virus were inoculated onto monolayers and after adsorption for 1 h at 37 °C the monolayers were washed and 6 ml EMEM containing 2% FCS and 0.5 % SeaKem ME agarose was added to each dish. After incubation at 37 °C in 5 % CO2 for the appropriate incubation period (usually 6 to 8 days) the virus from well-separated plaques was harvested by plunging a Pasteur pipette into the agarose directly over the plaque. The virus was then dispersed in 1 ml medium and frozen at -70 °C.
RESULTS
We have compared the ability of different strains of YF virus to kill mice using intracerebral, intranasal or intraperitoneal routes of inoculation. Preliminary studies showed that no YF virus was able to kill significant numbers (< 15 %) of mice following intraperitoneal inoculation (data not shown). However, different YF viruses were able to kill mice following either intracerebral or intranasal inoculation. The virulence of a virus will be examined using two criteria: ratio of p.f.u./LDso and the time taken for the virus to kill mice. For clarity the results will be divided into two sections: vaccine viruses (Table 2 ) and wild-type viruses (Table 3) .
Time to death of mice inoculated intracerebrally with vaccine YF viruses
Groups of six mice were inoculated intracerebrally with 10000 p.f.u, of the appropriate YF virus and then monitored daily. The results (Table 2) show that all mice died. However, the average survival times differed and the results have been arranged so that the average survival time following intracerebral inoculation is in ascending order. As can be seen, YF-FNV had the shortest time to death (6.2 + 0.3 days) whereas 17D-UK took longest to kill (11.2 + 0.8 days). On the basis of average survival time, three groups of viruses were distinguishable: < 7-8 days (group 1), 7.8 to 9.7 days (group 2) and > 10 days (group 3). Average survival time in group 1 was statistically different from that in group 3 (P < 0.05). In most cases, overall average survival time was independent of input virus concentration although four viruses (17D-SA, 17D-F, 17D-Aust and 17D-HoI1) took significantly longer to kill mice with low input virus concentrations (data not shown). Table 1 . Groupings were made on statistical differences between group 1 and group 3 following intracerebral inoculation (see text).
"l" A dose of 10000 p.f.u, was inoculated by the intracerebral route. :~ Average survival time is the sum of the day on which each mouse died divided by the number of dead mice.
Time to death of mice inoculated intracerebrally with wild-type YF viruses
Intracerebral administration of mice with different wild-type viruses resulted in death of all mice. The time to death following intracerebral inoculation differed for the viruses (Table 3) and three groups were distinguishable: < 7.8 days (group 1), 8-0 to 9.2 days (group 2) and > 9.5 days (group 3) on the basis that < 7-8 days was statistically different from > 9.5 days (P < 0-05). However, as in the case of the vaccines the results obtained for group 2 were not statistically different from either of the other two groups. Differences in time to death did not relate to the country or host from which the virus was isolated, or to the ability of the viruses to produce low or high titres in the newborn mouse brains. Also, time to death was not dose-dependent although YF-9026 took significantly longer to kill mice with low input virus concentrations (data not shown).
Intranasal inoculation of vaccine viruses
The neuroinvasiveness of YF vaccine viruses was investigated by inoculating mice intranasally ( Table 2 ). The most virulent virus was YF-FNV which had a p.f.u./LDs0 ratio of 104.28 and an average survival time of 10.1 _+ 0-7 days.
None of the eight 17D-204 vaccine viruses (Australia, Dakar, France, Holland, South Africa, United Kingdom, United States of America and West Germany) killed significant numbers of mice (although each virus was found to kill one or two mice, i.e. less than 20~ of mice). In contrast, the 17DD substrain vaccine virus manufactured in Brazil produced a p.f.u./LD5o ratio which was similar (10 g'! 1 ) to YF-FNV but the time to death was longer (17 days). This result was confirmed by repeating the tests with a different batch of 17DD-Brazil vaccine virus, and also by testing the Colombian derivative of 17DD vaccine. In comparison, the 17DD-Dakar derivative failed to kill mice following intranasal inoculation and appeared similar to the 17D-204 viruses.
Comparison of results obtained following intracerebral and intranasal inoculation revealed no correlations between average survival time using the intracerebral route and neuroinvasiveness following intranasal inoculation even though similar doses of virus were inoculated by the two routes (Table 2) .
Intranasal inoculation of wild-type YF viruses
Many of the stocks of the wild-type YF viruses had low infectivity titres. Consequently, only the wild-type preparations with titres of 107 p.f.u./ml or higher were examined for neuroinvasiveness following intranasal inoculation. Four of the seven viruses investigated killed mice (YF-AS, YF-B15, YF-BI2 and YF-B7) and three did not (YF-B9, YF-B5 and YF-9026) ( Table  3 ). The ratio of p.f.u./LDs0 and the average survival times for viruses that killed mice were similar for both wild-type and vaccine strains.
No correlation was observed between average survival time following intracerebral inoculation and neuroinvasiveness following intranasal inoculation even though similar doses of virus were administered by the two routes (Table 3) .
Comparison of virulence o]" YF virus Jor different strains of m&e following intranasal inoculation
The intranasal virulence of four of the viruses which had been shown to be neuroinvasive in strain TO mice (YF-FNV, YF-AS, YF-17DD-Braz-1 and -2) was compared in BALB/c mice (Table 4) . No significant differences in virulence were observed except that YF-AS took 3 days longer to kill BALB/c mice (P < 0.02). Therefore, using these two strains of mice, virulence did not seem to be host-related.
Examination of mouse virulence of plaque variants obtained from Asibi and B5 viruses
When plated on Vero cells under agarose overlay medium YF viruses produced a mixed population of plaque sizes, small plaques (SP) being defined as < 1.0 mm and large plaques (LP) > 1.0 mm in diam. Well-separated large and small plaques were selected as described earlier. This process was carried out for both YF-AS and YF-B5.
Following intracerebral inoculation, the time to death of the parent non-plaque-purified virus was compared with the plaque variants and found to be indistinguishable (Table 5) . However, following intranasal inoculation, the virulence of YF-AS-SP was greater than the parent YF-AS, while the virulence of YF-AS-LP could not be distinguished from the parent virus. Average survival time of the small plaque Asibi variant was similar to that of the AS parent, while AS-LP took significantly longer to kill mice (P < 0.05). In contrast, after intranasal inoculation of mice with either the B5 parent, B5-SP or B5-LP, only B5-LP was neurovirulent (105.3 p.f.u./LD5o). However, the high infectivity (>108 p.f.u./ml) in this preparation might account for its apparent virulence. Table 1 . Groupings were made on statistical differences between group 1 and group 3 following intracerebral inoculation. t Dose of virus was 1000 p.f.u. NT, Not tested as virus stocks < l07 p.f.u./ml. § Virus stocks with titres 107 p.f.u./ml and few or no deaths. 
Virulence of virus Jrom brains of mice inoculated intranasally
Two viruses which had been demonstrated to be virulent following intranasal inoculation (YF-FNV and YF-17DD-Braz-2) were inoculated intranasally and when mice appeared clinically sick, brains were removed and prepared as 20~o suckling mouse brain suspensions. Also, two other viruses which were not virulent following intranasal inoculation (YF-17D-SA and YF-17D-USA) were inoculated intranasally into groups of eight mice and when a mouse from either group appeared clinically sick, the brain was removed and prepared as above. These mouse brain preparations were used to inoculate mice intranasally to determine whether or not virulence had been altered. The virulence ratios of YF-FNV and YF-17DD-Braz-2 after selection as described above were indistinguishable from the original viruses while neither the selected YF-17D-SA nor YF-17D-USA killed any mice following intranasal inoculation (data not shown).
DISCUSSION
In this paper, we have compared the ability of different strains of YF virus to kill mice following different routes of inoculation. All strains of virus killed mice following intracerebral inoculation while preliminary studies have shown that none of the viruses examined killed significant numbers of mice following intraperitoneal inoculation (data not shown). In contrast, we were able to differentiate viruses by administering virus intranasally. Some viruses (YF-FNV, YF-AS, YF-BT, YF-B12, YF-B15, YF-17DD-Braz and YF-17DD-Col) killed mice following intranasal inoculation whereas others (YF-B5, YF-B9, YF-9026, YF-17DD-Dak and all YF-17D-204 viruses) did not.
We were surprised to find that some vaccine viruses were lethal following intranasal inoculation. Nine manufacturers have produced YF vaccines from the YF-17D-204 substrain and we have examined eight of these viruses and found that none killed mice following intranasal inoculation. On the other hand, two of the three vaccines derived from the 17DD substrain did kill mice. Not surprisingly, the French neurotropic vaccine virus, which is grown in mouse brain, killed mice following intranasal inoculation.
It is possible that the differences in neurovirulence for adult mice relate to passage history as 17DD viruses are at the 284th to 287th passage level, while 17D-204 viruses are only at the 233rd to 239th passage level (WHO, 1981) . This would not explain why 17DD-Dakar is not neurovirulent, and possibly the latter relates to different passage histories in different laboratories. Nonetheless, neurotropism may be associated with extra passaging of YF-17D viruses, especially since some vaccine lots which had been subcultured in excess of 300 passages were found to have increased neurovirulence with encephalitis in both humans and monkeys (Fox et al., 1942) . Also, Theiler (195 l) has observed that 17D viruses given additional passages in mouse brain reverted to virulence in rhesus monkeys.
Studies with other neurotropic flaviviruses (Nir et al., 1965; Nathanson, 1980; Monath et al., 1983) have shown that intranasal inoculation results in virus being transported to the olfactory lobe of the brain via the olfactory nerve. Some virus is detected in the lungs, but this is not considered to be directly involved in the disease process of neurotropic viruses (Nir et al., 1965) . Considering our results with YF virus, it would appear that some viruses have the ability to be neuroinvasive (i.e. neurovirulent) while others do not (i.e. avirulent). The determinants of neurovirulence are unknown but the results obtained with YF-AS and YF-B5 plaque variants suggest that not all virions in the population of the parent virus possess them. This is consistent with the studies of Holland and co-workers (for review, see Holland et al., 1982) who have shown that RNA viruses consist of a heterogeneous continually evolving population of virions. Possibly, neurovirulence and death due to YF virus depend on the relative proportion of 'neurotropic' virions in the population. We have grown a YF-AS parent preparation (on a separate occasion to that described in this paper but from the same seed stock) which was highly virulent (102"5v p.f.u./LDs0) like YF-AS-SP following intranasal inoculation, suggesting that the relative proportion of virions in the population differs between preparations (unpublished observations). This theory is supported by Liprandi (1981) and Liprandi & Walder (1983) who have shown that plaque variants of YF-17D-UK differ in virulence following intracerebral inoculation of adult mice and growth in human macrophages.
Finally, the relevance of mouse neurovirulence of YF virus to neurotropism in either monkeys or humans is not clear. Nevertheless, the demonstrated differences in mouse neurovirulence between YF viruses offer the possibility that mouse models can be used to investigate this problem in more detail.
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